Uni of Michigan Health System
Welcome,         Profile    Billing    Logout  
 6 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reichert, Zachery
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
TRAP, NCT03787680: Targeting Resistant Prostate Cancer With ATR and PARP Inhibition ( Trial)

Active, not recruiting
2
49
US
Olaparib, AZD2281, ceralasertib, AZD6738
University of Michigan Rogel Cancer Center
Prostate Cancer
01/23
01/27
NCT03556904: FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Completed
2
13
US
Ablative Radiation Therapy, Hormone therapy or chemotherapy, enzalutamide, abiraterone, docetaxel, cabazitaxel
University of Michigan Rogel Cancer Center
Prostate Cancer
07/23
07/23
A-DREAM, NCT05241860: Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer,

Active, not recruiting
2
79
US
Pharmacotherapy Discontinuation, Medication Discontinuation, Follow-Up, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC V8, Stage IVA Prostate Cancer AJCC V8, Stage IVB Prostate Cancer AJCC V8
11/25
09/33
SYNERGY-201, NCT06228053: Study of SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

Recruiting
2
53
US
SX-682, Enzalutamide, Xtandi
Syntrix Biosystems, Inc., National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer
06/26
06/28
FAALCON, NCT04748042: Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer

Recruiting
2
29
US
Abiraterone, Zytiga, Prednisone, External Beam Radiotherapy, Androgen Deprivation Therapy (ADT), Olaparib, Lynparza, AZD2281
University of Michigan Rogel Cancer Center
Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
05/25
05/25
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
NCT06616155: Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
1/2
39
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Enzalutamide, ASP9785, MDV 3100, MDV-3100, MDV3100, Xtandi, Ruxolitinib, INCB 018424, INCB-018424, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424
University of Michigan Rogel Cancer Center, Incyte Corporation
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
03/27
03/29
Baig, Yasmin
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26

Download Options